Cancer Research and Treatment10.4143/crt.2016.1912017492423-429Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study ResultsYeon Hee Park, Tae Yong Kim, Young-Hyuck Im, Keun-Seok Lee, In Hae Park, Joohyuk Sohn, Soo-Hyeon Lee, Seock-Ah Im, Jee Hyun Kim, Se Hyun Kim, Soo Jung Lee, Su-Jin Koh, Ki Hyeong Lee, Yoon Ji Choi, Eun Kyung Cho, Suee Lee, Seok Yun Kang, Jae Hong Seo, Sung-Bae Kim, Kyung Hae Jung,,
Breast Cancer10.1007/s12282-017-0826-42018253370-374Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabineXavier Pivot, Seock Ah Im, Matthew Guo, Frederik Marmé,,
Annals of Oncology10.1093/annonc/mdz100.032201930iii58A nationwide, multi-institutional retrospective study of efficacy and safety of eribulin in Korean breast cancer patients (REMARK)J. Jeong, M.H. Park, S.J. Lee, W.C. Noh, C.W. Jeon, S.W. Lee, G.S. Son, B.I. Moon, J.S. Lee, S.S. Kang,,
The Breast10.1016/s0960-9776(17)30708-7201736S53-S54Efficacy and Safety of Eribulin in Patients with HER2-Negative Metastatic Breast Cancer: Real Life ExperienceLarisa Zhilyaeva,
Clinical Breast Cancer10.3816/cbc.2006.n.044200674321-325Capecitabine/Cyclophosphamide/Methotrexate for Patients with Metastatic Breast Cancer: A Dose-Finding, Feasibility, and Efficacy StudyGabriella Mariani, Fausto Petrelli, Milvia Zambetti, Angela Moliterni, Angelica Fasolo, Alfonso Marchianó, Pinuccia Valagussa, Luca Gianni,
The Breast10.1016/s0960-9776(17)30718-x201736S57-S58Efficacy and Safety of Eribulin in Patients with Triple Negative Metastatic Breast Cancer: Real Life ExperienceLudmila Manzyuk Valentinova,
Clinical Breast Cancer10.3816/cbc.2010.n.0232010102160-163Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast CancerChris Twelves, Javier Cortes, Linda T. Vahdat, Jantien Wanders, Corina Akerele, Peter A. Kaufman,
Annals of Oncology10.1016/s0923-7534(20)32921-5201223ix129Pharmacokinetics of Eribulin Mesilate in Combination With Capecitabine in Patients With Advanced/Metastatic Cancer: Results From a Phase Ib Dose-Escalation StudyC.J. Twelves, M. Nasim, A. Anthoney, N. Cresti, C. Savulsky, C. Johnston, L. Reyderman, J. Wanders, R. Plummer, T.R.J. Evans,
Journal of Korean Medical Science10.3346/jkms.2000.15.5.5692000155569Clinical characteristics of Korean breast cancer patients in 1998. The Korean Breast Cancer Society The Korean Breast Cancer Society,,
Clinical Breast Cancer10.1016/j.clbc.2014.09.0012015151e55-e62Effects of Second and Subsequent Lines of Chemotherapy for Metastatic Breast CancerIn Hae Park, Keun Seok Lee, Jungsil Ro,